Updated Ordinary Index Rebalancing in the Solactive Pharma Breakthrough Value Index | September 2021

In the ordinary rebalance the following composition will be implemented effective open 20.09.2021:

ABBVIE INC
ALNYLAM PHARMACEUTICALS INC
BIOMARIN PHARMACEUTICAL INC
BRISTOL-MYERS SQUIBB CO
CHUGAI PHARMACEUTICAL CO LTD ORD
CLINUVEL PHARMACEUTICALS LTD
CSL LTD ORD
EISAI
EMERGENT BIOSOLUTIONS INC
ENDO INTERNATIONAL PLC
GENMAB A/S
GRIFOLS SA CLASS A
HALOZYME THERAPEUTICS INC
INCYTE CORP
IONIS PHARMACEUTICALS INC
JOHNSON & JOHNSON
KYOWA KIRIN CO LTD
NOVARTIS AG
OXFORD BIOMEDICA PLC
PTC THERAPEUTICS INC
ROCHE HOLDING AG
SANOFI SA
SAREPTA THERAPEUTICS INC
SINO BIOPHARMACEUTICAL LTD ORD
SUPERNUS PHARMACEUTICALS INC
SWEDISH ORPHAN BIOVITRUM AB
ULTRAGENYX PHARMACEUTICAL INC
UNITED THERAPEUTICS CORP
VERTEX PHARMACEUTICALS INC
XENCOR INC
ZAI LAB LTD